SM101: Phase Ib/IIa started

SuppreMol began a double-blind, placebo-controlled, dose-escalation European Phase Ib/IIa trial to evaluate intravenous SM101. Up to 36 patients will receive SM101 once weekly for 4 weeks in the Phase...